Editorial Correspondence
The Institute is an academic literature resource, not a clinical service, supplier, or regulatory body. We cannot provide medical advice, recommend or supply compounds, comment on the legality of importing investigational substances, or evaluate the practices of commercial vendors. Please review the categories below to identify the appropriate point of contact and to set realistic expectations regarding response.
Research and Literature Inquiries
Researchers seeking clarification on a specific point within one of our literature reviews, requesting that we examine a particular study or methodology in greater depth, or proposing additional references for inclusion are welcome to contact the editorial office. Please be specific: identify the article in question by URL, the section of interest, and the exact nature of your query. We respond to substantive inquiries from active researchers, graduate students, and clinical investigators as time allows.
Email: [email protected]
We are particularly receptive to inquiries that draw our attention to recently published primary literature warranting inclusion in updates, methodological critiques of studies we have summarized, or questions that have arisen during literature review or systematic review preparation. We are less able to respond to general orientation questions (such as "tell me about peptide X") that the existing reviews are intended to address.
Correction Requests
Accuracy matters. If you have identified a factual error in one of our literature reviews — a misattributed reference, an incorrect molecular weight or sequence, an inaccurate paraphrase of a study's findings, or a citation that fails to resolve — please notify the editorial office. We treat correction requests seriously and review them promptly, particularly those affecting mechanistic claims, clinical data, or safety information.
When submitting a correction request, please include: (1) the exact URL of the page containing the error; (2) a quotation or precise location of the disputed claim; (3) the primary source supporting the correct information; and (4) a brief explanation of why the current text is in error. Corrections accepted by the editorial board are implemented in the next scheduled update and acknowledged in the page's revision history where appropriate.
Email: [email protected]
Contributor Proposals
The Institute periodically engages additional peer reviewers and contributing editors with relevant expertise. We are particularly interested in researchers with active publication records in pharmacology, peptide chemistry, endocrinology, neuroscience, immunology, or translational medicine, and we welcome proposals from postdoctoral fellows, clinical fellows, and faculty interested in contributing to the systematic review and quality-control process.
Prospective contributors should submit: a brief statement of relevant expertise (a paragraph rather than a full CV is sufficient at this stage); a list of three to five representative publications; a proposed area of contribution (e.g., a specific peptide class, a methodological domain, or general editorial review); and any disclosures of relevant industry affiliations or potential conflicts of interest. The Institute maintains a strict policy of editorial independence from commercial sponsorship at the article level, and contributor relationships are structured to preserve that independence.
Email: [email protected]
Indexing and Library Partnerships
Academic libraries, research repositories, and indexing services interested in incorporating our literature reviews into broader discovery infrastructure are welcome to contact the editorial office. Our content is provided under a model that prioritizes accessibility for the research community; we cooperate readily with legitimate indexing and aggregation initiatives that support that mission. Please specify the indexing service, the proposed scope of inclusion, and any technical requirements (sitemap formats, metadata schemas, etc.) in your initial inquiry.
What We Cannot Provide
Several categories of inquiry consistently arrive at the editorial office and lie outside our scope:
- Medical or therapeutic advice. The Institute does not provide individual clinical guidance. Persons considering peptide therapeutics in any context should consult appropriately qualified healthcare professionals.
- Supplier recommendations. We do not evaluate, endorse, or maintain relationships with commercial peptide suppliers. Our content is independent of commercial sources and we are unable to comment on questions of product quality, sourcing, or vendor reliability.
- Legal or regulatory consultation. The legal status of investigational peptides varies substantially by jurisdiction and intended use. Questions regarding importation, possession, prescription, or research approval are properly directed to qualified legal counsel and relevant regulatory authorities.
- Pricing or purchasing assistance. The Institute does not sell, distribute, or facilitate the acquisition of any compound.
Response Expectations
Editorial correspondence is reviewed by the editorial board on a rolling basis, with priority given to correction requests and substantive academic inquiries. Routine messages typically receive a response within five to ten business days. Time-sensitive correction notices, particularly those affecting safety-related content, are handled on an expedited basis. We acknowledge receipt of all correspondence and do not maintain a "no-reply" inbox, though we do not respond to messages that are clearly out of scope as described above.
Mailing Address
For formal correspondence requiring postal delivery (rare, but occasionally needed for institutional partnerships or legal notice):
BioTech Pharma Research Institute
Editorial Office, Department of Pharmacology
Mailing address available on request via [email protected]
Most editorial business is conducted electronically; postal correspondence is reserved for matters where electronic delivery is unsuitable.